Gestational exposure to the AhR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin induces BRCA-1 promoter hypermethylation and reduces BRCA-1 expression in mammary tissue of rat offspring: Preventive effects of resveratrol

Molecular Carcinogenesis

Volumn 54, Issue 4, 2015, Pages 261-269

  Papoutsis, Andreas J ^a   Selmin, Ornella I ^a   Borg, Jamie L ^a   Romagnolo, Donato F ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Aromatic hydrocarbon receptor; BRCA 1; Epigenetics; Mammary carcinogenesis; Resveratrol

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; BRCA1 PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; DNA METHYLTRANSFERASE 1; RESVERATROL; ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; STILBENE DERIVATIVE; TERATOGENIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DRUG EFFECT; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC REGULATION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROMOTER REGION; PROTEIN EXPRESSION; RAT; RISK FACTOR; SPRAGUE DAWLEY RAT; ADVERSE EFFECTS; AGONISTS; ANIMAL; BREAST; BREAST NEOPLASMS; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; PATHOLOGY; PREGNANCY; TUMOR SUPPRESSOR GENE;

MURINAE; RATTUS;

ANIMALS; ANTICARCINOGENIC AGENTS; BRCA1 PROTEIN; BREAST; BREAST NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENES, BRCA1; MATERNAL EXPOSURE; PREGNANCY; PROMOTER REGIONS, GENETIC; RATS, SPRAGUE-DAWLEY; RECEPTORS, ARYL HYDROCARBON; STILBENES; TERATOGENS; TETRACHLORODIBENZODIOXIN;

EID: 84924755849     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22095     Document Type: Article

References (59)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-692.
2. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995; 9:444-450.
3. Magdinier F, Ribieras S, Lenoir GM, Frappart L, Dante R. Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region. Oncogene 1998; 17:3169-3176.
4. Mueller CR, Roskelley CD. Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res 2003; 5:45-52.
5. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006; 8:R38.
6. Butcher DT, Rodenhiser DI. Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours. Eur J Cancer 2007; 43:210-219.
7. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92:564-569.
8. Rice JC, Massey-Brown KS, Futscher BW. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998; 17:1807-1812.
9. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26:2126-2132.
10. Miyamoto K, Fukutomi T, Asada K, et al. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn J Clin Oncol 2002; 32:79-84.
11. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. BRCA1 promoter methylation in sporadic breast tumors: Relationship to gene expression profiles. Breast Cancer Res Treat 2005; 91:179-186.
12. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 2007; 96:11-15.
13. Jeffy BD, Hockings JK, Kemp MQ, et al. An estrogen receptor-alpha/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun/Fos transcription factors: repressive effects of p53 on BRCA-1 transcription. Neoplasia 2005; 7:873-882.
14. Hockings JK, Thorne PA, Kemp MQ, Morgan SS, Selmin O, Romagnolo DF. The ligand status of the aromatic hydrocarbon receptor modulates transcriptional activation of BRCA-1 promoter by estrogen. Cancer Res 2006; 66:2224-2232.
15. Papoutsis AJ, Lamore SD, Wondrak GT, Selmin OI, Romagnolo DF. Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells. J Nutr 2010; 140:1607-1614.
16. Papoutsis AJ, Borg JL, Selmin OI, Romagnolo DF. BRCA-1 promoter hypermethylation and silencing induced by the aromatic hydrocarbon receptor-ligand TCDD are prevented by resveratrol in MCF-7 cells. J Nutr Biochem 2012; 23:1324-1332.
17. Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 2003; 43:309-334.
18. Macpherson L, Matthews J. Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor α expression in human breast cancer cells. Cancer Lett 2010; 299:119-129.
19. Brown NM, Manzolillo PA, Zhang JX, Wang J, Lamartiniere CA. Prenatal TCDD and predisposition to mammary cancer in the rat. Carcinogenesis 1998; 19:1623-1629.
20. Jenkins S, Rowell C, Wang J, Lamartiniere CA. Prenatal TCDD exposure predisposes for mammary cancer in rats. Reprod Toxicol 2007; 23:391-396.
21. Russo J, Russo IH. Experimentally induced mammary tumors in rats. Breast Cancer Res Treat 1996; 39:7-20.
22. Bennett LM, Brownlee HA, Hagavik S, Wiseman RW. Sequence analysis of the rat Brca1 homolog and its promoter region. Mamm Genome 1999; 10:19-25.
23. Schlezinger JJ, Liu D, Farago M, et al. A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biol Chem 2006; 387:1175-1187.
24. Trombino AF, Near RI, Matulka RA, et al. Expression of the aryl hydrocarbon receptor/transcription factor (AhR) and AhR-regulated CYP1 gene transcripts in a rat model of mammary tumorigenesis. Breast Cancer Res Treat 2000; 63:117-131.
25. Banerjee S, Bueso-Ramos C, Aggarwal BB. Suppression of 7, 12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 2002; 62:4945-4954.
26. Russo J, Russo IH. Susceptibility of the mammary gland to carcinogenesis. II. Pregnancy interruption as a risk factor in tumor incidence. Am J Pathol 1980; 100:497-512.
27. Moral R, Santucci-Pereira J, Wang R, Russo IH, Lamartiniere CA, Russo J. In utero exposure to butyl benzyl phthalate induces modifications in the morphology and the gene expression profile of the mammary gland: an experimental study in rats. Environ Health 2011; 10:1-12.
28. Lewis BC, Hudgins S, Lewis A, et al. In utero and lactational treatment with 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin impairs mammary gland differentiation but does not block the response to exogenous estrogen in the postpubertal female rat. Toxicol Sci 2001; 62:46-53.
29. Fenton SE, Hamm JT, Birnbaum LS, Youngblood GL. Persistent abnormalities in the rat mammary gland following gestational and lactational exposure to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Sci 2002; 67:63-74.
30. Vorderstrasse BA, Fenton SE, Bohn AA, Cundiff JA, Lawrence BP. A novel effect of dioxin: Exposure during pregnancy severely impairs mammary gland differentiation. Toxicol Sci 2004; 78:248-257.
31. Xu X, Gammon MD, Zhang Y, et al. BRCA1promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 2009; 115:397-404.
32. Lamartiniere CA. Timing of exposure and mammary cancer risk. J Mammary Gland Biol Neoplasia 2002; 7:67-76.
33. Hushka LJ, Williams JS, Greenlee WF. Characterization of 2, 3, 7, 8-tetrachlorodibenzofuran-dependent suppression and AH receptor pathway gene expression in the developing mouse mammary gland. Toxicol Appl Pharmacol 1998; 152:200-210.
34. Russo J, Lynch H, Russo IH. Mammary gland architecture as a determining factor in the susceptibility of the human breast to cancer. Breast J 2001; 7:278-291.
35. Yang X, Solomon S, Fraser LR, et al. Constitutive regulation of CYP1B1 by the aryl hydrocarbon receptor (AhR) in pre-malignant and malignant mammary tissue. J Cell Biochem 2008; 104:402-417.
36. Leijs MM, Koppe JG, Olie K, et al. Delayed initiation of breast development in girls with higher prenatal dioxin exposure; a longitudinal cohort study. Chemosphere 2008; 6:999-1004.
37. Stejskalova L, Vecerova L, Perez LM, et al. Aryl hydrocarbon receptor and aryl hydrocarbon nuclear translocator expression inhuman and rat placentas and transcription activity in human trophoblast cultures. Toxicol Sci 2011; 123:26-36.
38. Fenton SE. Endocrine-disrupting compounds and mammary gland development: early exposure and later life consequences. Endocrinology 2006; 147:S18-S24.
39. Daniel JM, Spring CM, Crawford HC, Reynolds AB, Baig A. The p120(ctn)-binding partner Kaiso is a bi-modal DNA-binding protein that recognizes both a sequence-specific consensus and methylated CpG dinucleotides. Nucleic Acids Res 2002; 30:2911-2919.
40. Clouaire T, De Las Heras JI, Merusi C, Stancheva I. Recruitment of MBD1 to target genes requires sequence-specific interaction of the MBD domain with methylated DNA. Nucleic Acids Res 2010; 38:4620-4634.
41. Yoon HG, Chan DW, Reynolds AB, Qin J, Wong J. N-CoR mediates DNAmethylation-dependent repression through a methyl CpG binding protein Kaiso. Mol Cell 2003; 12:723-734.
42. Lopes EC, Valls E, Figueroa ME, et al. Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. Cancer Res 2008; 68:7258-7263.
43. Sarraf SA, Stancheva I. Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol Cell 2004; 15:595-605.
44. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006; 31:89-97.
45. Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 2008; 105:1680-1685.
46. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999; 22:37-43.
47. Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006; 1:23-32.
48. Iba MM, Fung J, Cooper KR, Thomas PE, Wagner GC, Park Y. Effect of gestational and lactational 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin exposure on the level and catalytic activities of hepatic microsomal CYP1A in prepubertal and adult rats. Biochem Pharmacol 2000; 59:1147-1154.
49. Suter M, Abramovici A, Showalter L, et al. In utero tobacco exposure epigenetically modifies placental CYP1A1 expression. Metabolism 2010; 59:1481-1490.
50. Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 2009; 47:2170-2182.
51. Singh CK, Kumar A, Hitchcock DB, et al. Resveratrol prevents embryonic oxidative stress and apoptosis associated with diabetic embryopathy and improves glucose and lipid profile of diabetic dam. Mol Nutr Food Res 2011; 55:1186-1196.
52. Jang JY, Park D, Shin S, et al. Antiteratogenic effect of resveratrol in mice exposed in utero to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. Eur J Pharmacol 2008; 591:280-293.
53. Singh NP, Singh US, Nagarkatti M, Nagarkatti PS. Resveratrol(3, 5, 4'-trihydroxystilbene) protects pregnant mother and fetus from the immunotoxic effects of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. Mol Nutr Food Res 2011; 55:209-219.
54. Botelho GG, Bufalo AC, Boareto AC, et al. Vitamin C and resveratrol supplementation to rat dams treated with di(2-ethylhexyl)phthalate: impact on reproductive and oxidative stress end points in male offspring. Arch Environ Contam Toxicol 2009; 57:785-793.
55. Bourque SL, Dolinsky VW, Dyck JR, Davidge ST. Maternal resveratrol treatment during pregnancy improves adverse fetal outcomes in a rat model of severe hypoxia. Placenta 2012; 33:449-452.
56. Gehm BD, Levenson AS, Liu H, et al. Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. J Steroid Biochem Mol Biol 2004; 3:223-234.
57. Zudaire E, Cuesta N, Murty V, et al. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest 2008; 118:640-650.
58. Evans BR, Karchner SI, Allan LL, et al. Repression of aryl hydrocarbon receptor (AHR) signaling by AHR repressor: role of DNA binding and competition for AHR nuclear translocator. Mol Pharmacol 2008; 73:387-398.
59. Hahn ME, Allan LL, Sherr DH. Regulation of constitutive and inducible AHR signaling: Complex interactions involving the AHR repressor. Biochem Pharmacol 2009; 77:485-497.